An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19 | Zendy

Katheron Intson | Zendy; Sachin Kumar | Zendy; Amy Botta | Zendy; Rachael Neckels | Zendy; Connie Leung | Zendy; Ali Jawaid | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19

Author(s) -

Katheron Intson,

Sachin Kumar,

Amy Botta,

Rachael Neckels,

Connie Leung,

Ali Jawaid

Publication year - 2020

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2020.20262

Subject(s) - hydroxychloroquine , medicine , covid-19 , betacoronavirus , intensive care medicine , virology , outbreak , disease , infectious disease (medical specialty)

A recent open-label study claimed that hydroxychloroquine and azithromycin represent promising new options for the treatment of SARS-CoV-2. This re-analysis reveals severe limitations in the methodology of this study, including ambiguous inclusion/exclusion of participant data and inconsistent analysis techniques, and yielded nonsignificant differences between control and treatment groups across any treatment days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research